4SC AG (FRA:VSC) 3-Year Book Growth Rate: -76.10% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 4SC AG 3-Year Book Growth Rate?

4SC AG FRA:VSC 3-Year Book Growth Rate is -76.10% as of Dec. 2025. The stock has 7 warning signs investors should review.

4SC AG's Book Value per Share for the quarter that ended in Dec. 2025 was €0.02.

During the past 12 months, 4SC AG's average Book Value per Share Growth Rate was -74.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was -76.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was -66.80% per year. During the past 10 years, the average Book Value per Share Growth Rate was -40.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of 4SC AG was 96.30% per year. The lowest was -76.10% per year. And the median was -19.10% per year.

4SC AG  (FRA:VSC) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

4SC AG 3-Year Book Growth Rate Related Terms

FRA:VSC vs VRTX, REGN, ALNY: 3-Year Book Growth Rate Comparison

For the Biotechnology subindustry, 4SC AG's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4SC AG 3-Year Book Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where 4SC AG's 3-Year Book Growth Rate falls into.


4SC AG 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of -76.10% mean?
4SC AG (FRA:VSC) has a 3-Year Book Growth Rate of -76.10% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for 4SC AG and its competitors.
Is 4SC AG's 3-Year Book Growth Rate too high?
4SC AG's current 3-Year Book Growth Rate is -76.10%.
How does 4SC AG's 3-Year Book Growth Rate compare to VRTX and REGN?
4SC AG's 3-Year Book Growth Rate of -76.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for 4SC AG and its competitors. 4SC AG's current 3-Year Book Growth Rate is -76.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4SC AG stock overvalued right now?
4SC AG (FRA:VSC) has a current 3-Year Book Growth Rate of -76.10%. The stock's GF Value™ is €3.51, compared to a current price of €0.10 — trading 97.2% below its estimated fair value. The current 3-Year Book Growth Rate is -76.10%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For 4SC AG (FRA:VSC), the current 3-Year Book Growth Rate is -76.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

4SC AG Business Description

Address Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.